Theravance Biopharma, Inc.: operating cash flow
Operating cash flow for Theravance Biopharma, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Theravance Biopharma, Inc. financial histories
What this measure means
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
Exact concept: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2015-01-01 to 2025-12-31. The SEC response was captured on 2026-09-19.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 238,541,000 | USD | 2026-03-23 | 10-K · 0001104659-26-033077 |
| 2024-01-01 | 2024-12-31 | -11,535,000 | USD | 2026-03-23 | 10-K · 0001104659-26-033077 |
| 2023-01-01 | 2023-12-31 | -26,997,000 | USD | 2025-03-07 | 10-K · 0001558370-25-002447 |
| 2022-01-01 | 2022-12-31 | -186,991,000 | USD | 2024-03-01 | 10-K · 0001558370-24-002267 |
| 2021-01-01 | 2021-12-31 | -207,858,000 | USD | 2023-03-01 | 10-K · 0001558370-23-002595 |
| 2020-01-01 | 2020-12-31 | -250,403,000 | USD | 2023-03-01 | 10-K · 0001558370-23-002595 |
| 2019-01-01 | 2019-12-31 | -238,197,000 | USD | 2022-02-28 | 10-K · 0001558370-22-002373 |
| 2018-01-01 | 2018-12-31 | -112,867,000 | USD | 2021-02-26 | 10-K · 0001558370-21-002006 |
| 2017-01-01 | 2017-12-31 | -201,052,000 | USD | 2020-02-27 | 10-K · 0001558370-20-001644 |
| 2016-01-01 | 2016-12-31 | -98,989,000 | USD | 2019-02-28 | 10-K · 0001558370-19-001346 |
| 2015-01-01 | 2015-12-31 | -168,857,000 | USD | 2018-02-28 | 10-K · 0001047469-18-001160 |
Related financial histories
- Theravance Biopharma, Inc.: total assets
- Theravance Biopharma, Inc.: stockholders equity
- Theravance Biopharma, Inc.: cash and cash equivalents
- Theravance Biopharma, Inc.: net income or loss
- Theravance Biopharma, Inc.: capital expenditure payments
- Theravance Biopharma, Inc.: revenue
- Theravance Biopharma, Inc.: contract revenue excluding tax
- Theravance Biopharma, Inc.: financing cash flow
- Theravance Biopharma, Inc.: investing cash flow
- Theravance Biopharma, Inc.: retained earnings or deficit
- Theravance Biopharma, Inc.: basic weighted-average shares
- Theravance Biopharma, Inc.: diluted weighted-average shares
- Theravance Biopharma, Inc.: basic earnings per share
- Theravance Biopharma, Inc.: diluted earnings per share
- Theravance Biopharma, Inc.: income tax expense or benefit
- Theravance Biopharma, Inc.: net property, plant and equipment
- Theravance Biopharma, Inc.: share-based compensation expense
- Theravance Biopharma, Inc.: operating income or loss
- Theravance Biopharma, Inc.: current assets
- Theravance Biopharma, Inc.: interest expense
- Theravance Biopharma, Inc.: current liabilities
- Theravance Biopharma, Inc.: current accounts payable
- Theravance Biopharma, Inc.: net current accounts receivable
- Theravance Biopharma, Inc.: common-stock repurchase payments
- Theravance Biopharma, Inc.: operating expenses
- Theravance Biopharma, Inc.: net inventory
- Theravance Biopharma, Inc.: selling, general and administrative expense
- Theravance Biopharma, Inc.: research and development expense
Inspect the source
- Entity
- Theravance Biopharma, Inc. / CIK 0001583107
- Captured
- 2026-09-19T11:19:18.148Z
- SEC response SHA-256
3526ec0d3f81387c03caa1ef2904c1cfb1ce908cb40338946f71478c67c40012
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001583107.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))